- Home
- BKU vs VRNA Comparison
BKU vs VRNA Comparison
Compare BKU & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKU
- VRNA
- Stock Information
- Founded
- BKU 2009
- VRNA 2005
- Country
- BKU United States
- VRNA United Kingdom
- Employees
- BKU N/A
- VRNA N/A
- Industry
- BKU Savings Institutions
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- BKU Finance
- VRNA Health Care
- Exchange
- BKU Nasdaq
- VRNA Nasdaq
- Market Cap
- BKU 2.7B
- VRNA 2.2B
- IPO Year
- BKU 2011
- VRNA 2017
- Fundamental
- Price
- BKU $37.81
- VRNA $34.66
- Analyst Decision
- BKU Hold
- VRNA Strong Buy
- Analyst Count
- BKU 10
- VRNA 6
- Target Price
- BKU $34.60
- VRNA $39.33
- AVG Volume (30 Days)
- BKU 871.9K
- VRNA 949.3K
- Earning Date
- BKU 10-22-2024
- VRNA 10-31-2024
- Dividend Yield
- BKU 3.07%
- VRNA N/A
- EPS Growth
- BKU N/A
- VRNA N/A
- EPS
- BKU 2.25
- VRNA N/A
- Revenue
- BKU $881,684,000.00
- VRNA N/A
- Revenue This Year
- BKU N/A
- VRNA N/A
- Revenue Next Year
- BKU $8.12
- VRNA $1,077.76
- P/E Ratio
- BKU $16.76
- VRNA N/A
- Revenue Growth
- BKU N/A
- VRNA N/A
- 52 Week Low
- BKU $21.02
- VRNA $11.39
- 52 Week High
- BKU $39.51
- VRNA $34.74
- Technical
- Relative Strength Index (RSI)
- BKU 62.15
- VRNA 74.23
- Support Level
- BKU $34.62
- VRNA $33.29
- Resistance Level
- BKU $38.19
- VRNA $34.74
- Average True Range (ATR)
- BKU 0.97
- VRNA 1.40
- MACD
- BKU 0.28
- VRNA 0.29
- Stochastic Oscillator
- BKU 90.38
- VRNA 98.76
About BKU BankUnited Inc.
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located primarily throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.